form25.htm
 
UNITED STATES
 
SECURITIES AND EXCHANGE COMMISSION
 
Washington, D.C.  20549
 

 
FORM 25
 
NOTIFICATION OF REMOVAL FROM LISTING AND/OR
REGISTRATION UNDER SECTION 12(b) OF THE
SECURITIES EXCHANGE ACT OF 1934
 
Commission File Number 001-31812

BIOSANTE PHARMACEUTICALS, INC.
(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
 
111 Barclay Boulevard, Lincolnshire, Illinois 60069, (847) 478-0500
(Address, including zip code, and telephone number, including area code, of Issuer’s principal executive offices)
 
Common Stock
(Description of class of securities)
 
Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
 
£  
17 CFR 240.12d2-2(a)(1)
 
£  
17 CFR 240.12d2-2(a)(2)
 
£  
17 CFR 240.12d2-2(a)(3)
 
 £  
17 CFR 240.12d2-2(a)(4)
 
£  
Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange.1
 
 x  
Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with the rules of the Exchange and the requirements of 17 CFR 240.12d2-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
 
Pursuant to the requirements of the Securities Exchange Act of 1934, BioSante Pharmaceuticals, Inc. certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
 
 
 Date:
  November 2, 2007
 By:
  /s/ Phillip B. Donenberg   
 Title: 
 Chief Financial Officer,
Treasurer and Secretary

 
 
1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-2 as applicable.  See General Instructions.